Palvella Therapeutics, Inc. stock is trading on the Nasdaq exchange, and the NDA review for its product QTORIN is currently underway.
3 reports, 2 independent
Updated Mon 00:00
No new developments lately
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Palvella Therapeutics, Inc. stock is trading on the Nasdaq exchange, and the NDA review for its product QTORIN is currently underway.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Phase 3 results led to NDA submission to the FDA.1 source
Palvella Therapeutics stock trades on Nasdaq while undergoing NDA review for QTORIN.1 source
Keep exploring
The entities involved
Related events
- BioPharma stock was traded on the NASDAQ stock exchange on July 30, 2026, with its performance tracked by financial blogs.
- Perdoceo Education Corporation stock is trading on the electronic stock exchange, with increased stake activity noted during the Q1 reporting period.
- Alvotech utilized Nasdaq for its public stock listing and is currently undergoing comprehensive review by the FDA for biosimilar applications.
- Incannex Healthcare Inc. stock was traded on the Nasdaq exchange on June 29, 2026.
- Vera Therapeutics Inc. stock traded on the Nasdaq exchange on August 4, 2026, and received analyst ratings from Bank of America.